QoL from TASCO1: health-related quality of life of trifluridine/tipiracil-bevacizumab and capecitabine-bevacizumab as first-line treatments in metastatic colorectal cancer patients not eligible for intensive chemotherapy-Results from the TASCO1 phase II study
Authors
Moiseyenko, VSaunders, Mark P
Wasan, HS
Argiles, G
Borg, C
Creemers, GJ
Fedyanin, M
Glynne-Jones, R
Pfeiffer, P
Punt, CJA
Stroyakovskiy, D
Ten Tije, AJ
de Wouw, AWV
Kanehisa, A
Fougeray, R
Sabater, J
Amellal, N
Van Cutsem, E
Affiliation
Clinical and Research Center of Specialized Types of Medical Care (Oncological), St. PetersburgIssue Date
2019
Metadata
Show full item recordCitation
Moiseyenko V, Saunders MP, Wasan HS, Argiles G, Borg C, Creemers G-J, et al. QoL from TASCO1: health-related quality of life of trifluridine/tipiracil-bevacizumab and capecitabine-bevacizumab as first-line treatments in metastatic colorectal cancer patients not eligible for intensive chemotherapy�Results from the TASCO1 phase II study. J Clin Oncol. 2019;37(4_suppl):676-.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2019.37.4_suppl.676Additional Links
https://dx.doi.org/10.1200/JCO.2019.37.4_suppl.676Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2019.37.4_suppl.676